Corticosterone decreases the activity of rat glutamate transporter type 3 expressed in Xenopus oocytes

Steroids
Maehwa KangSang-Hwan Do

Abstract

Glucocorticoids can increase the extracellular concentrations of glutamate, the major excitatory neurotransmitter. We investigated the effects of corticosterone on the activity of a glutamate transporter, excitatory amino acid carrier 1 (EAAC1; also called excitatory amino acid transporter type 3 [EAAT3]), and the roles of protein kinase C (PKC) and phosphatidylinositol 3-kinase (PI3K) in regulating these effects. Rat EAAC1 was expressed in Xenopus oocytes by injecting mRNA. L-Glutamate (30 μM)-induced membrane currents were measured using the two-electrode voltage clamp technique. Exposure of these oocytes to corticosterone (0.01-1 μM) for 72 h decreased EAAC1 activity in a dose-dependent fashion, and this inhibition was incubation time-dependent. Corticosterone (0.01 μM for 72 h) significantly decreased the V(max), but not the K(m), of EAAC1 for glutamate. Furthermore, pretreatment of oocytes with staurosporine, a PKC inhibitor, significantly decreased EAAC1 activity (1.00±0.06 to 0.70±0.05 μC; P<0.05). However, no statistical differences were observed between oocytes treated with staurosporine, corticosterone, or corticosterone plus staurosporine. Similar patterns of responses were achieved by chelerythrine or calphostin C, ...Continue Reading

References

Nov 5, 1990·Brain Research·M P ArmaniniR M Sapolsky
Jun 1, 1997·British Journal of Anaesthesia·M J Hudspith
Feb 24, 1998·European Journal of Pharmacology·K MinamiR A Harris
Jan 5, 2000·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·E S BrownV A Nejtek
Oct 18, 2000·European Journal of Pharmacology·L Angelucci
Mar 20, 2001·Archives of Neurology·N J Maragakis, J D Rothstein
May 23, 2001·Progress in Neurobiology·N C Danbolt
Aug 8, 2001·Journal of Neuroendocrinology·M Joëls
Feb 5, 2002·European Archives of Psychiatry and Clinical Neuroscience·C Höschl, T Hajek
Sep 25, 2003·Alcoholism, Clinical and Experimental Research·Bryon AdinoffMark J Williams
Apr 28, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Claudia-Carolin WeberWalter E Müller

❮ Previous
Next ❯

Citations

May 1, 2021·Frontiers in Cellular Neuroscience·Renae M RyanAnnalisa Scimemi

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.